Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Current assets:
Cash	$ 73	$ 0
Prepaid expenses and other current assets	38	0
Total current assets	111	0
Deferred initial public offering costs	1,674	0
Property, plant and equipment, net	110	0
Other assets	100	0
Total assets	1,995	0
Current liabilities:
Accrued expenses and accounts payable	2,526	223
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	4,838	0
Income tax payable	1	0
Total current liabilities	7,365	223
Warrant liability	32,555	0
Total liabilities	39,920	223
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 43,750,684 and 37,231,342 issued and outstanding at September 30, 2016 and March 31, 2016, respectively	1	1
Common shares subscribed	(1)	(1)
Additional paid-in capital	17,415	1,434
Accumulated deficit	(55,340)	(1,657)
Total shareholders’ deficit	(37,925)	(223)
Total liabilities and shareholders’ deficit	$ 1,995	$ 0